10 Hottest Mid-Cap Stocks So Far in 2025

2. Inari Medical Inc (NASDAQ:NARI)
  • YTD Performance: 53.57%

Inari Medical Inc (NASDAQ:NARI) makes medical devices to treat blot clots in veins and their main products are designed to remove clots from deep veins and pulmonary arteries without using clot-dissolving drugs.

Much like the company I’ve discussed above, Inari Medical has also risen sharply due to an acquisition deal being announced. Stryker announced it’s buying Inari Medical for $4.9 billion at $80 per share in cash.

In their last reported quarter (Q3 2024), they pulled in revenue of $153.4 million, up 21.4% from the same quarter the previous year. That’s impressive growth, no doubt. However, they’re still operating at a loss, with a GAAP operating loss of $13.6 million in that quarter. It’s worth noting that this is a bigger loss compared to the $2.1 million operating income they had in the same quarter of 2023.

Again, I think the acquisition deal should be focused on more than the financials here.